Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
暂无分享,去创建一个
Paula M Jacobs | E. Neuwelt | Suzanne G. Watnick | B. Hamilton | C. Varallyay | P. Jacobs | Edward A Neuwelt | Bronwyn E Hamilton | Csanad G Varallyay | William R Rooney | Robert D Edelman | Suzanne G Watnick | R. Edelman | W. Rooney | Suzanne Watnick | Bronwyn E. Hamilton
[1] W. Heindel,et al. First‐pass and equilibrium‐MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study , 2004, NMR in biomedicine.
[2] Michael Jerosch-Herold,et al. THE POTENTIAL OF FERUMOXYTOL NANOPARTICLE MAGNETIC RESONANCE IMAGING, PERFUSION, AND ANGIOGRAPHY IN CENTRAL NERVOUS SYSTEM MALIGNANCY: A PILOT STUDY , 2007, Neurosurgery.
[3] W. K. Bolton,et al. Pharmacokinetic Study of Ferumoxytol: A New Iron Replacement Therapy in Normal Subjects and Hemodialysis Patients , 2005, American Journal of Nephrology.
[4] E. Neuwelt,et al. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours , 2004, Neuropathology and applied neurobiology.
[5] D. Bilecen,et al. MR angiography with blood pool contrast agents , 2007, European Radiology.
[6] Martin R Prince,et al. Blood pool MR angiography of aortic stent-graft endoleak. , 2004, AJR. American journal of roentgenology.
[7] J. Cunningham,et al. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: A Sufficient Reason to Avoid Gadolinium‐Based Contrast in All Patients with Renal Impairment? , 2008, Seminars in dialysis.
[8] Tom Mikkelsen,et al. Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial , 2004, Journal of magnetic resonance imaging : JMRI.
[9] R. Weissleder,et al. Delivery of virus-sized iron oxide particles to rodent CNS neurons. , 1994, Neurosurgery.
[10] Frederik Barkhof,et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. , 2008, Brain : a journal of neurology.
[11] R. Lauffer,et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.
[12] Ernst J. Rummeny,et al. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro , 2004, European Radiology.
[13] P. Jacobs,et al. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.
[14] Sudhir V. Shah,et al. New insights into nephrogenic systemic fibrosis. , 2007, Journal of the American Society of Nephrology : JASN.
[15] G. Bongartz,et al. Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency? , 2007, Magnetic Resonance Materials in Physics, Biology and Medicine.
[16] E. Neuwelt,et al. An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. , 2005, AJNR. American journal of neuroradiology.
[17] Sudhir V. Shah,et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. , 2007, The New England journal of medicine.
[18] E. Neuwelt,et al. In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging. , 2007, American journal of physiology. Cell physiology.
[19] T. Grobner,et al. Gadolinium and nephrogenic systemic fibrosis. , 2007, Kidney international.
[20] James I. Cohen,et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. , 2002, AJNR. American journal of neuroradiology.
[21] Wei Li,et al. First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agent , 2005, Journal of magnetic resonance imaging : JMRI.
[22] J. L. Abraham,et al. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. , 2008, European journal of radiology.
[23] Bruno Brochet,et al. Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging , 2004, Investigative radiology.
[24] E. Neuwelt,et al. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. , 2005, AJNR. American journal of neuroradiology.